Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel The Importance of CYP2C19*2 Genotyping

被引:110
作者
Alexopoulos, Dimitrios [1 ]
Dimitropoulos, Gerasimos [1 ]
Davlouros, Periklis [1 ]
Xanthopoulou, Ioanna [1 ]
Kassimis, George [1 ]
Stavrou, Eleana F. [2 ]
Hahalis, George [1 ]
Athanassiadou, Aglaia [2 ]
机构
[1] Patras Univ Hosp, Dept Cardiol, Patras 26500, Greece
[2] Univ Patras, Sch Med, Dept Gen Biol, GR-26110 Patras, Greece
关键词
CYP2C19; high-dose clopidogrel; pharmacogenetics; platelet reactivity; prasugrel; PERCUTANEOUS CORONARY INTERVENTION; OF-FUNCTION POLYMORPHISM; ASPIRIN-TREATED PATIENTS; TIMI; 38; TRIAL; ARTERY-DISEASE; ANTIPLATELET THERAPY; CYP2C19; GENOTYPE; DOUBLE-BLIND; CARE ASSAY; INHIBITION;
D O I
10.1016/j.jcin.2010.12.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The primary aim of the study was to determine the antiplatelet effects of prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity (HTPR) after percutaneous coronary intervention (PCI) and, secondarily, their relation to cytochrome (CYP) 2C19*2 carriage. Background High on-treatment platelet reactivity after clopidogrel administration after PCI is linked to the loss-of-function CYP2C19*2 allele and accompanied by an increased risk of adverse events. Methods We performed a prospective, randomized, single-blind, crossover study of platelet inhibition by prasugrel 10 mg/day versus high-dose 150 mg/day clopidogrel in 71 (of 210 screened; 33.8%) post-PCI patients with HTPR. Platelet function was assessed by the Verify Now assay (Accumetrics, San Diego, California), and real-time polymerase chain reaction genotyping was performed for CYP2C19*2 carriage. Results The primary endpoint of platelet reactivity (measured in platelet reactivity units) at the end of the 2 treatment periods was lower after prasugrel compared with clopidogrel (least-squares estimates 129.4, 95% confidence interval [Cl]: 111.1 to 147.7 versus 201.7, 95% Cl: 183.2 to 220.2; p < 0.001). The least-squares mean difference between the 2 treatments was -122.9 (95% Cl: -166.7 to -79.2, p < 0.001), and -47.5 (95% Cl: -79.5 to -15.4, p = 0.004), in carriers and noncarriers of at least 1 mutant allele, respectively. The HTPR rates were lower for prasugrel than for clopidogrel, in all patients (7.5% vs. 35.8%, p < 0.001), in carriers (5.3% vs. 47.4%, p = 0.007), and in noncarriers (8.8% vs. 29.4%, p = 0.005), respectively. Conclusions In patients with HTPR after PCI, prasugrel is more effective compared with high clopidogrel in reducing platelet reactivity, particularly in CYP2C19*2 carriers. Genotyping guidance might be helpful only in case an increased clopidogrel maintenance dose is considered. (Prasugrel Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Post Percutaneous Coronary Intervention (PCI); NCT01109784) (J Am Coll Cardiol Intv 2011;4:403-10) (C) 2011 by the American College of Cardiology Foundation
引用
收藏
页码:403 / 410
页数:8
相关论文
共 36 条
[1]   Clopidogrel 150 mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention Results From the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) Randomized Study [J].
Aleil, Boris ;
Jacquemin, Laurent ;
De Poli, Fabien ;
Zaehringer, Michel ;
Collet, Jean-Philippe ;
Montalescot, Gilles ;
Cazenave, Jean-Pierre ;
Dickele, Marie-Claude ;
Monassier, Jean-Pierre ;
Gachet, Christian .
JACC-CARDIOVASCULAR INTERVENTIONS, 2008, 1 (06) :631-638
[2]   Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study [J].
Angiolillo, Dominick J. ;
Shoemaker, Steven B. ;
Desai, Bhaloo ;
Yuan, Hang ;
Charlton, Ronald K. ;
Bernardo, Esther ;
Zenni, Martin M. ;
Guzman, Luis A. ;
Bass, Theodore A. ;
Costa, Marco A. .
CIRCULATION, 2007, 115 (06) :708-716
[3]   Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary Syndromes Results of the SWAP (SWitching Anti Platelet) Study [J].
Angiolillo, Dominick J. ;
Saucedo, Jorge F. ;
DeRaad, Roger ;
Frelinger, Andrew L. ;
Gurbel, Paul A. ;
Costigan, Timothy M. ;
Jakubowski, Joseph A. ;
Ojeh, Clement K. ;
Effron, Mark B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 56 (13) :1017-1023
[4]  
[Anonymous], 2009, LANCET EDITORIAL, V373
[5]  
[Anonymous], 2010, FDA DRUG SAF COMM RE
[6]   Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity [J].
Barker, Colin M. ;
Murray, Sarah S. ;
Teirstein, Paul S. ;
Kandzari, David E. ;
Topol, Eric J. ;
Price, Matthew J. .
JACC-CARDIOVASCULAR INTERVENTIONS, 2010, 3 (10) :1001-1007
[7]  
Borlak J, 2002, CLIN CHEM, V48, P1592
[8]   Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation [J].
Breet, Nicoline J. ;
van Werkum, Jochem W. ;
Bouman, Heleen J. ;
Kelder, Johannes C. ;
Ruven, Henk J. T. ;
Bal, Egbert T. ;
Deneer, Vera H. ;
Harmsze, Ankie M. ;
van der Heyden, Jan A. S. ;
Rensing, Benno J. W. M. ;
Suttorp, Maarten J. ;
Hackeng, Christian M. ;
ten Berg, Jurrien M. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (08) :754-762
[9]   Pharmacogenetic Testing for Clopidogrel Using the Rapid INFINITI Analyzer A Dose-Escalation Study [J].
Gladding, Patrick ;
White, Harvey ;
Voss, Jamie ;
Ormiston, John ;
Stewart, Jim ;
Ruygrok, Peter ;
Bvaldivia, Badi ;
Baak, Ruth ;
White, Catherine ;
Webster, Mark .
JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (11) :1095-1101
[10]   Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity [J].
Gurbel, PA ;
Bliden, KP ;
Hiatt, BL ;
O'Connor, CM .
CIRCULATION, 2003, 107 (23) :2908-2913